Trend of A-share and Hong Kong stock innovative drug sector this week
In the first week of April 2022, a total of 26 stocks in the innovative drug sector in mainland and Hong Kong rose, 25 stocks fell, and the trading of cornerstone pharmaceutical-b was suspended. Among them, the top three were Kaifa pharmaceutical-b (+ 150.98%), Yunding xinyao-b (+ 21.88%), and platinum pharmaceutical-b (+ 16.33%). The top three declines were Shanghai Junshi Biosciences Co.Ltd(688180) u (-8.86%), Betta Pharmaceuticals Co.Ltd(300558) 8.29%, and Shanghai Allist Pharmaceuticals Co.Ltd(688578) u (-8.13%). This week, the A-share innovative drug sector fell 7.72%, underperforming the CSI 300 index by 1.06pp, and biomedicine fell 2.64%. In the past six months, A-share innovative drugs have fallen by 15.03%, underperforming the CSI 300 index by 12.15pp, and biomedicine has fallen by 17.54%. This week, the innovative drug sector of Hong Kong stocks fell by 1.91%, underperforming the Hang Seng Index by 0.76pp, and Hang Seng healthcare rose by 0.37%. Over the past six months, innovative drugs in Hong Kong stocks have fallen by 20.93%, underperforming the Hang Seng Index by 13.53pp, and Hang Seng health care has fallen by 28.21%.
Progress of key innovative drugs in China
In April, two new drugs were approved for marketing in China. This week, two drugs were approved for listing, and one innovative drug was approved for new indications. Nmpa approved technetium [99mTc] tetrophosphine from GE Medical for radionuclide imaging. Nmpa approved pemitinib of Cinda bio for the treatment of adult patients with advanced, metastatic or unresectable cholangiocarcinoma with FGFR2 fusion or rearrangement. Posaconazole of MSD has been approved as a new indication to prevent patients aged 13 and over who are at increased risk of invasive Aspergillus and Candida infections due to severe immune deficiency.
Progress of overseas key innovative drugs
In April, two new drugs were approved by FDA for marketing. This week, two new drugs were approved, namely bioxceltherapeutics, dexmedetomidine of Inc. and alpelisib of Novartis pharmaceuticals Corp. In April, no new drugs were approved for marketing in Europe. In April, no new drugs were approved for marketing in Japan.
This week’s small topic – research and development progress of GLP-1 target
There are 37 GLP-1 inhibitors under development worldwide. There are 28 double target projects and 3 multi-target projects, including 2 approved for listing, 2 phase III clinical projects, 6 phase II clinical projects, 2 phase I / II clinical projects and 10 phase I clinical projects. China is studying 24. There are 19 double target projects and 1 multi-target project, including 2 phase III clinical projects, 4 phase II clinical projects and 6 phase I clinical projects.
Progress of global key innovative drug transactions this week
This week, there were 10 key transactions in the world, and there were 2 key transactions with disclosed amount, involving companies including werewolf therapeutics and jazz pharmaceuticals, platinum medicine and AstraZeneca.
Risk warning: drug price reduction risk; The implementation progress of medical reform policy is lower than the expected risk; Risk of R & D failure.
